Life

Vitamin B1 (thiamine) is a water-soluble B vitamin. As a cofactor of many enzymes, it is essential for the proper functioning of many body systems and organs, including metabolic and energy metabolism. In extreme cases, vitamin B1 deficiency causes neurodegenerative disorders, including beri-beri, or cognitive impairment resulting from encephalopathy. B1 avitaminosis may result from increased demand, dietary errors, malabsorption, or excessive loss. Thiamine supplementation is used in cases of vitamin B1 deficiency or for preventative measures in situations of increased demand. Vitamin B1 can be administered enterally or parenterally (intravenously, intramuscularly, subcutaneously). The route and dose depend on the individual patient’s clinical situation. Hypersensitivity to vitamin B1 is rare and appears to be primarily associated with rapid intravenous infusion of large doses of thiamine hydrochloride over a short period (intravenous bolus). Hypersensitivity to thiamine administered by routes other than intravenous or intramuscular injection appears to be an incidental phenomenon. Thiamine should also be considered as an occupational allergen. The mechanism of thiamine hypersensitivity has not been clearly elucidated. However, considering the clinical nature and dynamics of the reaction, the most likely reaction seems to be an immediate type of hypersensitivity reaction (immunoglobulin E (IgE)-dependent), in which thiamine (but not its metabolites) acts as a hapten. Diagnosing hypersensitivity to vitamin B1 is difficult due to the lack of validated tests for additional testing. In individuals requiring thiamine supplementation who have experienced hypersensitivity to intramuscular or intravenous administration of this vitamin, switching to oral administration may be considered (provided this does not reduce treatment efficacy). This form of supplementation is usually well tolerated by individuals allergic to parenteral thiamine. However, if enteral supplementation does not guarantee the maintenance of therapeutic potential, thiamine desensitization may be considered, which seems to be an effective therapeutic method in such a clinical situation.

Pinus koraiensis leaves are known for various bioactivities, including anti-cancer, anti-obesity, anti-diabetic, and anti-hyperlipidemic effects. This study aimed to compare the essential oil from P. koraiensis leaves (EPO) and the supercritical-CO₂-extracted oil (SPO) for physicochemical traits, antibacterial and anticancer activities, and anti-inflammatory/antioxidant effects, and profiled fatty acids by means of GC-MS. SPO showed stronger antimicrobial activity than EPO against Streptococcus mutans, whereas EPO was more active against Candida albicans. In HaCaT keratinocytes and THP-1 monocytic cell line, SPO more effectively suppressed LPS-induced ROS and attenuated TNF-α and IL-6 upregulation. Across a panel of human cancer cell lines, SPO exerted greater cytotoxicity, particularly in non–small cell lung, prostate, and colon cancers. GC–MS revealed greater compositional diversity in SPO (16 fatty acids, 10 unique), while linolelaidic acid was detected only in EPO; pentadecenoic acid was abundant in all oils. Collectively, SPO demonstrates broader bioactivity and richer fatty-acid diversity than EPO, supporting its potential as a functional food or medicinal ingredient.

Obstructive sleep apnea syndrome (OSAS) is a common disorder with established cardiovascular and metabolic risks. Positive airway pressure (PAP) therapy remains the standard of care; however, its long-term effectiveness is often limited by poor compliance and adherence. This study sought to explore clinical and device-related factors influencing PAP use, with emphasis on pressure variability in Auto-PAP users and comorbidities such as COPD. We performed a retrospective analysis of 359 patients with OSAS who were treated with CPAP, Auto-PAP, or BiPAP devices at the Marius Nasta Institute of Pneumology between January 2022 and July 2024. Compliance was measured as the proportion of days the device was used, whereas adherence was estimated through average nightly hours of use. Patient data were stratified by demographic, clinical, and device-related characteristics. Statistical testing included Chi-square, Wilcoxon rank-sum, and correlation analyses. Demographics did not significantly differ between compliant and non-compliant groups. Notably, Auto-PAP users with greater pressure variability (>10 cm H₂O) had significantly lower compliance (p = 0.001). Nasal mask preference was also associated with poorer compliance (p = 0.030). Multivariate models further revealed that atrial fibrillation reduced the likelihood of good adherence (OR = 0.319, 95% CI 0.137–0.746). These results highlight the importance of monitoring pressure variability, device type, and comorbidities to personalize PAP therapy and improve long-term outcomes.